Focused On-demand Library for Angiogenic factor with G patch and FHA domains 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q8N302

UPID:

AGGF1_HUMAN

Alternative names:

Angiogenic factor VG5Q; G patch domain-containing protein 7; Vasculogenesis gene on 5q protein

Alternative UPACC:

Q8N302; O00581; Q53YS3; Q9BU84; Q9NW66

Background:

Angiogenic factor with G patch and FHA domains 1, also known as Angiogenic factor VG5Q, plays a pivotal role in promoting angiogenesis and endothelial cell proliferation. Its ability to bind to endothelial cells suggests an autocrine mechanism of action, enhancing vascular formation and growth.

Therapeutic significance:

Linked to Klippel-Trenaunay syndrome, a congenital disease marked by vascular malformations and tissue hypertrophy, this protein's gene variants are crucial in disease manifestation. Targeting its pathway offers a promising avenue for therapeutic intervention in vascular anomalies.